Bausch + Lomb (NYSE:BLCO) Announces Earnings Results, Beats Expectations By $0.02 EPS

Bausch + Lomb (NYSE:BLCO) posted its earnings results on Wednesday. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02, Zacks reports. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. Bausch + Lomb’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.07) EPS.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Strong quarter and raised guidance — Q1 delivered 6% constant-currency revenue growth, adjusted EBITDA up 59% (adjusted EBITDA margin 16.1%), and management raised full-year revenue guidance to $5.42–$5.52B and adjusted EBITDA to $1.01–$1.06B.
• Pharma/dry-eye momentum — Pharmaceuticals grew 12% CC with MIEBO up ~33% and Xiidra up ~30% as the company shifts from launch to growth, driving meaningful revenue and margin leverage.
• Active pipeline and higher R&D investment — R&D spend rose ~15–17% while the company filed an NDA for LUMIFY Next, completed a CE submission for Silara, and began shipping PreserVision AREDS 3 and Blink Triple Care PF, highlighting commercialization progress.
• Contact lenses and premium mix driving margin — Contact lens revenue grew 5% with daily SiHy up ~23–25%, and premium products now represent 26% of U.S. sales (vs. 19% a year ago), supporting higher-margin mix and share gains.
• Surgical segment near-term headwinds — Surgical revenue rose just 1% as weather-related procedure disruptions, reimbursement pressures, and a U.S. surgical field-force rebuild caused short-term impact, though management expects sequential improvement.

Bausch + Lomb Price Performance

Shares of NYSE:BLCO traded up $0.56 during trading on Thursday, reaching $15.90. The company had a trading volume of 742,043 shares, compared to its average volume of 417,035. The company has a fifty day moving average of $16.69 and a two-hundred day moving average of $16.51. The stock has a market capitalization of $5.67 billion, a P/E ratio of -15.59, a price-to-earnings-growth ratio of 0.66 and a beta of 0.65. Bausch + Lomb has a 12 month low of $10.83 and a 12 month high of $18.92. The company has a current ratio of 1.55, a quick ratio of 1.04 and a debt-to-equity ratio of 0.77.

Insider Transactions at Bausch + Lomb

In related news, CFO Sam Eldessouky purchased 4,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were purchased at an average price of $17.13 per share, with a total value of $68,520.00. Following the acquisition, the chief financial officer directly owned 403,130 shares of the company’s stock, valued at approximately $6,905,616.90. This represents a 1.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brent L. Saunders purchased 14,700 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $17.14 per share, for a total transaction of $251,958.00. Following the acquisition, the chief executive officer directly owned 966,575 shares in the company, valued at approximately $16,567,095.50. The trade was a 1.54% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 33,300 shares of company stock valued at $570,868 in the last quarter. Insiders own 1.45% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

Institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Bausch + Lomb by 729.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after buying an additional 2,042 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Bausch + Lomb by 104.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after purchasing an additional 1,136 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after purchasing an additional 1,403 shares during the last quarter. Focus Partners Wealth bought a new position in shares of Bausch + Lomb during the 3rd quarter valued at $170,000. Finally, Invesco Ltd. bought a new position in shares of Bausch + Lomb during the 4th quarter valued at $178,000. Institutional investors own 11.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Evercore set a $18.00 target price on shares of Bausch + Lomb and gave the stock an “in-line” rating in a report on Monday, January 5th. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Bausch + Lomb in a report on Thursday. Citigroup upped their target price on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $19.00 target price on shares of Bausch + Lomb in a report on Friday, January 9th. Finally, Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $18.08.

More Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q1 beat — BLCO reported $0.08 EPS vs. $0.06 consensus and revenue of ~$1.244B (≈+9% YoY), showing top-line growth and an earnings beat that supports near-term momentum. Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
• Positive Sentiment: Raised FY2026 guidance — management increased revenue guidance to $5.42B–$5.52B and is targeting ~$1.01B–$1.06B of adjusted EBITDA, which materially improved the company’s forward profitability outlook. Bausch + Lomb raises 2026 revenue guidance to $5.42B-$5.52B while projecting $1.01B-$1.06B adjusted
• Positive Sentiment: R&D and scientific visibility — the company will present more than 40 scientific studies at the ARVO meeting, bolstering pipeline credibility and long-term product/market potential. Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 ARVO Annual Meeting
• Neutral Sentiment: Management tone — CEO Brent Saunders emphasized “sustainable growth and margin expansion” and continued investment in the pipeline on the earnings call and slides; useful for guidance credibility but not a guaranteed near-term earnings driver. Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript
• Negative Sentiment: GAAP loss and margins — GAAP net loss of $71M and a reported negative net margin (~7%) mean the company is not yet consistently profitable on a GAAP basis, which keeps valuation metrics (negative P/E) and leverage under scrutiny. Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.